Covered recipient · General Payments record
MICHAEL DIAN YU
Allopathic & Osteopathic Physicians Ophthalmology
General Payments · PY2023–2024
$4,451.45
- Reported across 41 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,497.41 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Alcon Laboratories Inc | $394.93 | 5 |
| Regeneron Pharmaceuticals, Inc. | $311.90 | 3 |
| Alimera Sciences, Inc. | $299.41 | 3 |
| Genentech USA, Inc. | $176.69 | 1 |
| Genentech, Inc. | $143.18 | 2 |
| Daxor Corporation | $127.64 | 1 |
| UCB, Inc. | $43.66 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Alcon Vision LLC | $38.97 | 01/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110686780 | CMS |
| Alcon Vision LLC | $60.68 | 01/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110686784 | CMS |
| Alcon Vision LLC | $56.34 | 01/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110686782 | CMS |
| Alcon Vision LLC | $140.94 | 01/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110686788 | CMS |
| Alcon Vision LLC | $98.00 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110686786 | CMS |
| Alimera Sciences, Inc. | $118.41 | 07/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1092833979 | CMS |
| Alimera Sciences, Inc. | $81.00 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1092828023 | CMS |
| Alimera Sciences, Inc. | $100.00 | 09/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1092839254 | CMS |
| Daxor Corporation | $127.64 | 02/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136815786 | CMS |
| Genentech USA, Inc. | $176.69 | 07/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133072099 | CMS |
| Genentech, Inc. | $76.06 | 03/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133072107 | CMS |
| Genentech, Inc. | $67.12 | 12/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133072103 | CMS |
| Regeneron Pharmaceuticals, Inc. | $131.43 | 05/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114406784 | CMS |
| Regeneron Pharmaceuticals, Inc. | $94.44 | 07/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114406786 | CMS |
| Regeneron Pharmaceuticals, Inc. | $86.03 | 09/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114406788 | CMS |
| UCB, Inc. | $43.66 | 06/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143048856 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2023, 2024
- Source files
- Dataset page · Bulk file · PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.